Toggle light / dark theme

There’s a tiny, slow-burning ‘fuse’ attached to the ends of all our chromosomes, and as we naturally age, each of our cells loses more and more of that life-giving line.

Researchers in South Korea have now shown this fuse, known as the telomere, is unusually short in the cells of elderly people who are relatively healthy but have noticed early signs of depressive symptoms and cognitive decline, such as memory loss.

The randomized controlled trial presents more evidence for the telomere hypothesis of aging, which posits that all cells hit a point where they can no longer divide and replicate.

“That’s got molecules in it that will prevent cancer, among other things” like anti-inflammatory properties, he said. Some older research has shown, for example, that green tea consumption might be linked to a lower risk of stomach cancer.

Sinclair also said he takes supplements (like those sold on the Tally Health website) that contain resveratrol, which his team’s research has shown can extend the lifespan of organisms like yeast and worms.

While the compound, famously found in red wine, is known to have anti-inflammatory, anti-cancer, heart health, and brain health benefits, the research is mixed on if or how well such benefits can be achieved in humans through a pill.

Futurist Ray Kurzweil is still making waves years after his initial singularity claims as artificial intelligence continues to progress. With singularity milestones coming, Kurzweil believes immortality is achievable by 2030. Kurzweil’s predictions are met with a healthy dose of skepticism. A new video from the YouTube channel Adagio revisits futurist Ray Kurzweil’s ideas about how for humans, both singularity and immortality are shockingly imminent—as in, potentially just seven years away.

Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs, has announced it has received protocol concurrence from the FDA for its companion dog longevity study.

Longevity. Technology: Loyal is on a mission is to help dogs everywhere live longer, healthier lives – and that means taking on the development of the first FDA-approved drugs explicitly intended to extend lifespan and healthspan. On the path to FDA approval, Loyal must run a clinical trial that objectively and robustly demonstrates that its drug extends dogs’ healthy lifespan – and does so safely. However, no-one has developed a dog – or human – longevity drug before, so Loyal is building the path to FDA approval largely from scratch.

Today, Loyal has announced that last week it learned from the FDA that the company has received protocol concurrence for its companion dog longevity study. This is good news for the longevity biotech sector, especially welcome as it comes on the same day that tech lender Silicon Valley Bank collapsed and was put under the control of the US Federal Deposit Insurance Corporation – news that left biotechs and VCs reeling.

The industry is gaining ground in understanding how aging affects reliability, but more variables make it harder to fix.

Circuit aging is emerging as a first-order design challenge as engineering teams look for new ways to improve reliability and ensure the functionality of chips throughout their expected lifetimes.

The need for reliability is obvious in data centers and automobiles, where a chip failure could result in downtime or injury. It also is increasingly important in mobile and consumer electronics, which are being used for applications such as in-home health monitoring or for navigation, and where the cost of the devices has been steadily rising. But aging also needs to be assessed in the context of variation models from the foundries, different use cases that may stress various components in different ways, and different power and thermal profiles, all of which makes it harder to accurately predict how a chip will behave over time.

Ray Kurzweil — The Singularity IS NEAR — part 2! We’ll Reach IMMORTALITY by 2030
Get ready for an exciting journey into the future with Ray Kurzweil’s The Singularity IS NEAR — Part 2! Join us as we explore the awe-inspiring possibilities of what could be achieved before 2030, including the potential for humans to reach immortality. We’ll dive into the incredible technology that could help us reach this singularity and uncover what the implications of achieving immortality could be. Don’t miss out on this fascinating insight into the future of mankind!
In his book “The Singularity Is Near”, futurist and inventor Ray Kurzweil argues that we are rapidly approaching a point in time known as the singularity. This refers to the moment when artificial intelligence and other technologies will become so advanced that they surpass human intelligence and change the course of human evolution forever.

Kurzweil predicts that by 2030, we will reach a crucial milestone in our technological progress: immortality. He bases this prediction on his observation of exponential growth in various fields such as genetics, nanotechnology, and robotics, which he believes will culminate in the creation of what he calls “nanobots”.

These tiny robots, according to Kurzweil, will be capable of repairing and enhancing our bodies at the cellular level, effectively making us immune to disease, aging, and death. Additionally, he believes that advances in brain-computer interfaces will allow us to upload our consciousness into digital form, effectively achieving immortality.

Kurzweil’s ideas have been met with both excitement and skepticism. Some people see the singularity as a moment of great potential, a time when we can overcome our biological limitations and create a better future for humanity. Others fear the singularity, believing that it could lead to the end of humanity as we know it.